Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialyl-fucosyl type 2 chain polylactosamine.

The quantity of tumor-associated antigens carrying type 2 chain polylactosamines with four types of fucosyl determinants, LeX (X-hapten), poly-LeX, sialyl LeX, and LeY (Y-hapten), present in sera of patients with various malignant and non-malignant disorders, as well as the qualitative chemical properties of the carrier molecules in sera, have been investigated using four monoclonal antibodies, each of which defines one of these determinants. The following findings are of particular importance: the serum levels of LeX defined by antibody FH2 and poly-LeX defined by ACFH18 in patients with cancer were occasionally high (incidence about 10%); however, the majority of patients did not show elevated levels; the serum level of the antigen, defined by monoclonal antibody FH6 (termed sialyl LeX-i since this determinant is carried by i antigen), was significantly high in patients with cancers originating from organs from which adenocarcinomas often develop. For example, among various types of lung cancer, only adenocarcinoma but not squamous cell carcinoma, small cell carcinoma, or large cell carcinoma showed a high level of sialyl LeX-i antigen in sera. The incidence of high antigen levels in sera of patients with adenocarcinomas of lung was as high as 76% of the observed cases; the serum level of Ley (Y-hapten) was frequently high in patients with hepatoma (incidence, 34%); sialyl LeX-i antigen was separated on gel filtration as a glycoprotein with an average molecular weight greater than 10(6). It was characterized by its susceptibility to basehydrolysis, Pronase digestion, and sialidase and endo-beta-galactosidase treatment and is assumed to be a high molecular weight mucin-type glycoprotein; sialyl LeX-i antigen expressed in sera of patients with cancer was soluble in perchloric acid, while the same antigen in sera of patients with noncancerous diseases and normal subjects was mostly insoluble in perchloric acid. LeX, a poly-LeX, and essentially all LeY antigens in sera of patients with cancer were perchloric acid-insoluble.

[1]  S. Hakomori,et al.  Novel fucolipids accumulating in human adenocarcinoma. I. Glycolipids with di- or trifucosylated type 2 chain. , 1984, The Journal of biological chemistry.

[2]  S. Hakomori,et al.  Location and distribution of difucoganglioside (VI3NeuAcV3III3Fuc2nLc6) in normal and tumor tissues defined by its monoclonal antibody FH6. , 1985, Cancer research.

[3]  D. Solter,et al.  The hapten structure of a developmentally regulated glycolipid antigen (SSEA-1) isolated from human erythrocytes and adenocarcinoma: a preliminary note. , 1981, Biochemical and biophysical research communications.

[4]  S. Hakomori,et al.  A series of human erythrocyte glycosphingolipids reacting to the monoclonal antibody directed to a developmentally regulated antigen SSEA-1. , 1982, The Journal of biological chemistry.

[5]  S. Hakomori,et al.  Monoclonal antibodies PMN 6, PMN 29, and PM-81 bind differently to glycolipids containing a sugar sequence occurring in lacto-N-fucopentaose III. , 1984, Archives of biochemistry and biophysics.

[6]  H. Koprowski,et al.  Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. , 1983, Cancer research.

[7]  S. Hakomori,et al.  The monoclonal antibody directed to difucosylated type 2 chain (Fuc alpha 1 leads to 2Gal beta 1 leads to 4[Fuc alpha 1 leads to 3]GlcNAc; Y Determinant). , 1983, The Journal of biological chemistry.

[8]  S. Hakomori,et al.  Enzymatic basis for the accumulation of glycolipids with X and dimeric X determinants in human lung cancer cells (NCI-H69). , 1985, The Journal of biological chemistry.

[9]  P. Terasaki,et al.  Use of monoclonal antibodies to sialylated Lewisx and sialylated Lewisa for serological tests of cancer. , 1985, Cancer research.

[10]  D. Solter,et al.  Stage-specific embryonic antigen involves αl→ 3 fucosylated type 2 blood group chains , 1981, Nature.

[11]  S. Hakomori,et al.  Blood Group Antigens , 1974 .

[12]  J. H. Shaper,et al.  My-1, the human myeloid-specific antigen detected by mouse monoclonal antibodies, is a sugar sequence found in lacto-N-fucopentaose III. , 1983, Blood.

[13]  W. Watkins.  Biochemistry and Genetics of the ABO, Lewis, and P blood group systems. , 1980, Advances in human genetics.

[14]  S. Hakomori,et al.  Novel fucolipids accumulating in human adenocarcinoma. II. Selective isolation of hybridoma antibodies that differentially recognize mono-, di-, and trifucosylated type 2 chain. , 1984, The Journal of biological chemistry.

[15]  P. Hanfland,et al.  Immunochemistry of the Lewis Blood‐Group System , 1981 .

[16]  S. Hakomori,et al.  Glycosphingolipids as tumor-associated and differentiation markers. , 1983, Journal of the National Cancer Institute.

[17]  I. Bernstein,et al.  A granulocyte reactive monoclonal antibody, 1G10, identifies the Gal beta 1-4 (Fuc alpha 1-3)GlcNAc (X determinant) expressed in HL-60 cells on both glycolipid and glycoprotein molecules. , 1983, Blood.

[18]  Y. Masuho,et al.  Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. , 1984, Cancer research.

[19]  P. Sturgeon,et al.  Lex, the Spurned Antigen of the Lewis Blood Group System 1 , 1974, Vox sanguinis.

[20]  M. Brockhaus,et al.  A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. , 1982, The Journal of biological chemistry.

[21]  J. Minna,et al.  Many monoclonal antibodies with an apparent specificity for certain lung cancers are directed against a sugar sequence found in lacto-N-fucopentaose III. , 1983, Archives of biochemistry and biophysics.

[22]  M. Herlyn,et al.  Specific antigen in serum of patients with colon carcinoma. , 1981, Science.

[23]  M. Lan,et al.  Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. , 1985, Cancer Research.

[24]  H. Harris,et al.  Structure and function of the Ca antigen. , 1983, British Journal of Cancer.

[25]  E. Hounsell,et al.  Marker of peripheral blood granulocytes and monocytes of man recognized by two monoclonal antibodies VEP8 and VEP9 involves the trisaccharide 3‐fucosyl‐N‐acetyllactosamine , 1983, European journal of immunology.

[26]  S. Hakomori,et al.  Novel fucolipids accumulating in human adenocarcinoma. III. A hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3NeuAcV3III3Fuc2nLc6). , 1984, The Journal of biological chemistry.

[27]  I. Mushahwar,et al.  Prevalence of hepatitis B e antigen and its antibody as detected by radioimmunoassays , 1978, Journal of medical virology.

[28]  S. Hakomori,et al.  Characterization of sialosylated Lewisx as a new tumor-associated antigen. , 1984, Cancer research.